Related references
Note: Only part of the references are listed.Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
J. Weber et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Lactate dehydrogenase: a marker of diminished antitumor immunity
Sandra Van Wilpe et al.
ONCOIMMUNOLOGY (2020)
Systemic Therapy for Melanoma: ASCO Guideline
Rahul Seth et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy of immune checkpoint inhibitors for in-transit melanoma
Emilia Nan Tie et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis
John T. Miura et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
Viola Franke et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
A systematic review and meta-analysis of locoregional treatments for in-transit melanoma
Tavis Read et al.
JOURNAL OF SURGICAL ONCOLOGY (2019)
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Elisa A. Rozeman et al.
LANCET ONCOLOGY (2019)
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
Robert H. Andtbacka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
O. Michielin et al.
ANNALS OF ONCOLOGY (2019)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
Junko Johansson et al.
FRONTIERS IN ONCOLOGY (2018)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P. B. Chapman et al.
ANNALS OF ONCOLOGY (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT
C. Kunte et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients
Max F. Madu et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
CO2 Laser Treatment for Regional Cutaneous Malignant Melanoma Metastases
Jorien A. van Jarwaarde et al.
DERMATOLOGIC SURGERY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
John F. Thompson et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy
Rebecca L. Read et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma
Roger Olofsson et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2013)
Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha
Jan P. Deroose et al.
CURRENT OPINION IN ONCOLOGY (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy
TM Pawlik et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Share Paper
